Drugs used in the treatment of rheumatoid arthritis: Relationship between current use and cardiovascular risk factors

Archives of Drug Information

Volumn 2, Issue 2, 2009, Pages 34-40

  Rho, Young Hee ^a   Oeser, Annette ^a   Chung, Cecilia P ^a   Milne, Ginger L ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimalarials; Cardiovascular risk; Corticosteroids; COX 2 inhibitor; Leflunomide; Methotrexate; NSAIDs; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RACE DIFFERENCE; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

EID: 77950257640     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2009.00019.x     Document Type: Article

References (29)

1. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: Relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53.
2. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously-Predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
3. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002;359:1173-7.
4. Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30.
5. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
6. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
7. Brooks PM. Non-steroidal anti-inflammatory drugs. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology, 3rd edition. London: Elsevier; 2003:377-84.
8. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289-94.
9. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: Effects on lipids, glucose and thrombosis. Lupus 1996;5(suppl 1):S16-22.
10. Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006;8:R186.
11. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008;58:2105-12.
12. Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, et al. Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 2008;58:2662-9.
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
14. Montuschi P, Barnes P, Roberts LJ. Insights into oxidative stress: The isoprostanes. Curr Med Chem 2007;14:703-17.
15. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2007;2:221-6.
16. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2007.
17. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16:505-11.
18. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
19. Pearson H. When good cholesterol turns bad. Nature 2006;444:794-5.
20. Rho YH, Oeser A, Chung CP, Morrow JD, Stein CM. Drugs to treat systemic Lupus Erythematosus: Relationship between current use and cardiovascular risk factors. Arch Drug Inf 2008;1:23-8.
21. Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: Impact on cardiovascular risk. Drugs 2002;62:605-16.
22. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: A review. Rheumatology (Oxford) 2004;43:267-71.
23. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am J Med 1994;96:254-9.
24. Anigbogu CN, Adigun SA, Inyang I, Adegunloye BJ. Chloroquine reduces blood pressure and forearm vascular resistance and increases forearm blood flow in healthy young adults. Clin Physiol 1993;13:209-16.
25. Musabayane CT, Musvibe A, Wenyika J, Munjeri O, Osim EE. Chloroquine influences renal function in rural Zimbabweans with acute transient fever. Ren Fail 1999;21:189-97.
26. Rozman B, Praprotnik S, Logar D, Tomsic M, Hojnik M, Kos-Golja M, et al. Leflunomide and hypertension. Ann Rheum Dis 2002;61:567-9.
27. Coblyn JS, Shadick N, Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum 2001;44:1048-51.
28. Huvers FC, Popa C, Netea MG, van den Hoogen FH, Tack CJ. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007;66:558-9.
29. Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, etal. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503-7.